US Bancorp DE Buys 1,948 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

US Bancorp DE grew its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 146.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,278 shares of the company’s stock after acquiring an additional 1,948 shares during the period. US Bancorp DE’s holdings in Roivant Sciences were worth $38,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of ROIV. Mutual of America Capital Management LLC lifted its holdings in shares of Roivant Sciences by 0.4% in the 2nd quarter. Mutual of America Capital Management LLC now owns 327,079 shares of the company’s stock worth $3,457,000 after buying an additional 1,142 shares during the period. Acadian Asset Management LLC lifted its stake in Roivant Sciences by 23.2% in the second quarter. Acadian Asset Management LLC now owns 8,510 shares of the company’s stock worth $89,000 after acquiring an additional 1,603 shares during the period. nVerses Capital LLC bought a new position in Roivant Sciences during the 2nd quarter worth about $34,000. DNB Asset Management AS increased its position in Roivant Sciences by 6.4% during the 2nd quarter. DNB Asset Management AS now owns 56,022 shares of the company’s stock valued at $592,000 after purchasing an additional 3,386 shares during the period. Finally, Point72 Hong Kong Ltd bought a new stake in shares of Roivant Sciences in the 2nd quarter valued at about $36,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, Director Financial Lp Qvt sold 876,000 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $11.82, for a total value of $10,354,320.00. Following the completion of the transaction, the director now owns 22,179,358 shares of the company’s stock, valued at approximately $262,160,011.56. This trade represents a 3.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Matthew Gline sold 1,983,257 shares of Roivant Sciences stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $11.79, for a total transaction of $23,382,600.03. Following the sale, the chief executive officer now owns 17,870,543 shares of the company’s stock, valued at $210,693,701.97. The trade was a 9.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,577,309 shares of company stock valued at $42,151,184 in the last quarter. 7.90% of the stock is currently owned by corporate insiders.

Roivant Sciences Trading Down 0.4 %

NASDAQ ROIV opened at $11.16 on Tuesday. The firm’s fifty day simple moving average is $11.75 and its two-hundred day simple moving average is $11.32. The firm has a market capitalization of $8.25 billion, a P/E ratio of 1.98 and a beta of 1.24. Roivant Sciences Ltd. has a 12-month low of $8.56 and a 12-month high of $13.06.

Analyst Upgrades and Downgrades

ROIV has been the topic of a number of recent research reports. Bank of America increased their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research note on Wednesday, September 11th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.93.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.